Table 3

Echocardiographic Parameters of AVERT Patients, by Type of Valve

Silzone-Coated Valve Prosthesis (n = 285)Conventional Valve Prosthesis (n = 290)
Echocardiographic follow-up (months)23 ± 722 ± 8
LVEDV (ml)112 ± 44108 ± 42
LVESV (ml)48 ± 3844 ± 35
LVEF (%)61 ± 1262 ± 12
All prosthetic valve regurgitation, n (%)
 Definitive29 (10.2%)21 (7.2%)
 Possible8 (2.8%)11 (3.8%)
Severity of PVR
 Mild13 (4.6%)13 (4.5%)
 Moderate13 (4.6%)9 (3.1%)
 Severe2 (0.7%)0 (0.0%)
PVR, mitral valven = 111n = 119
 Definitive13 (11.7%)10 (8.4%)
 Possible4 (3.6%)8 (6.7%)
PVR, aortic valven = 201n = 196
 Definitive16 (8.0%)11 (5.6%)
 Possible4 (2.0%)3 (1.5%)

All numbers shown are mean ± SD, unless noted otherwise. There were no statistical differences between the two groups.

AVERT = Artificial Valve Endocarditis Reduction Trial; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; PVR = paravalvular regurgitation.